Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cohesion Technologies, U.S. Surgical Corp. sales and marketing update

U.S. Surgical received exclusive marketing rights to CSON's CoStasis

Read the full 92 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE